Cevipabulin

DB12533InvestigationalSmall molecule

Cevipabulin has been used in trials studying the treatment and educational/counseling/training of Tumors and Neoplasms.

Mechanism: Pharmacologically active on Tubulin alpha chain and Tubulin
Curator reviewed
Formula / weight: C₁₈H₁₈ClF₅N₆O · 464.83 g/mol (avg)
Code names: TTI-237

Resolves to

Compound

Structure

InChIKeyZUZPCOQWSYNWLU-VIFPVBQESA-NSMILESCNCCCOC1=CC(F)=C(C(F)=C1)C1=C(N[C@@H](C)C(F)(F)F)N2N=CN=C2N=C1Cl

What you can answer from here — as of July 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Cevipabulin, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.